Zobrazeno 1 - 10
of 15
pro vyhledávání: '"FJ Salmeron Navas"'
Autor:
EM Barreiro Fernandez, FJ Salmeron Navas, CM Dominguez Santana, MA Blanco Castaño, E Rios Sanchez
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27e7eae581220d461707856e57a5e598
https://doi.org/10.1136/ejhpharm-2023-eahp.137
https://doi.org/10.1136/ejhpharm-2023-eahp.137
Autor:
EM Barreiro Fernandez, CM Dominguez Santana, E Rios Sanchez, MA Blanco Castaño, FJ Salmeron Navas
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcca05d45ca386128f8061e78bba405e
https://doi.org/10.1136/ejhpharm-2023-eahp.135
https://doi.org/10.1136/ejhpharm-2023-eahp.135
Autor:
FJ Salmeron Navas, M Dominguez Cantero, EJ Alegre-Del Rey, Silvia Fénix-Caballero, EM Barreiro-Fernandez, C Moreno-Ramos
Publikováno v:
Section 1: Introductory statements and governance.
Background and importance ALK gene mutation occurs in 3–5% of patients with non-small cell lung cancer (NSCLC). Brigatinib and alectinib are potent ALK tyrosine kinase inhibitors, indicated in NSCLC. Aim and objectives The aim of this study was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::017174bafb51a17a40e8399c644d7cc4
https://doi.org/10.1136/ejhpharm-2021-eahpconf.2
https://doi.org/10.1136/ejhpharm-2021-eahpconf.2
Autor:
C Martínez Díaz, EM Barreiro Fernandez, EJ Alegre-Del Rey, FJ Salmeron Navas, M Dominguez Cantero, S. Fénix Caballero
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance The SARS-CoV-2 pandemic could have changed the clinical management of cancer patients because of travel restrictions, overloading of hospital systems and disruption of treatment. Lung cancer patients constitute a vulnerable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0090f1368b02ccbf0f2c2319dd0d6ac4
https://doi.org/10.1136/ejhpharm-2021-eahpconf.128
https://doi.org/10.1136/ejhpharm-2021-eahpconf.128
Autor:
C Moreno-Ramos, MP Briceño-Casado, FJ Salmeron-Navas, M Dominguez Cantero, EM Barreiro-Fernandez
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance Intravenous immunoglobulin (IVIG) therapy is relatively expensive and requires careful use. IVIG dosing is based on actual body weight (ABW) but it is mainly distributed in the extracellular and intravascular space and minim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3473c1e260a778ebe71159899e1503e8
https://doi.org/10.1136/ejhpharm-2020-eahpconf.23
https://doi.org/10.1136/ejhpharm-2020-eahpconf.23
Autor:
M Dominguez Cantero, EM Barreiro-Fernandez, Silvia Fénix-Caballero, FJ Salmeron Navas, C Martinez-Diaz
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance The therapeutic option in patients with metastatic non-small cell lung cancer (mNSCLC) after chemotherapy is based on the immune checkpoint inhibitors (ICI). Aim and objectives The aim of this study was to analyse the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67d90b621601d359cee59de50035a064
https://doi.org/10.1136/ejhpharm-2020-eahpconf.198
https://doi.org/10.1136/ejhpharm-2020-eahpconf.198
Autor:
M Dominguez-Cantero, Silvia Fénix-Caballero, FJ Salmeron-Navas, EM Barreiro Fernandez, C Martinez-Diaz
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance According to the PARAMOUNT trial, induction chemotherapy with a platin/pemetrexed combination and pemetrexed maintenance therapy reduced the risk of progression free survival (PFS) and overall survival (OS) in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::153397e0dae1dc8c941d4878ec4c3daa
https://doi.org/10.1136/ejhpharm-2020-eahpconf.174
https://doi.org/10.1136/ejhpharm-2020-eahpconf.174
Autor:
JM Borrero-Rubio, M Dominguez-Cantero, M Camean-Castillo, Silvia Fénix-Caballero, FJ Salmeron-Navas
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background and importance Regorafenib, ramucirumab and cabozantinib are used as secondline therapy in patients with hepatocarcinoma and alfa-fetoprotein value ≥400 ng/mL (HCC-AP ≥400). There are no direct comparisons among them. Aim and objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b05e27bf5de352ca0e4e2ead430f9d9
https://doi.org/10.1136/ejhpharm-2020-eahpconf.25
https://doi.org/10.1136/ejhpharm-2020-eahpconf.25
Autor:
FJ Salmeron-Navas, JM Borrero-Rubio, E Rios-Sanchez, Silvia Fénix-Caballero, Mdp Briceño-Casado, Gil-Sierra, M Camean-Castillo, EJ Alegre-Del Rey, J Diaz-Navarro, C Martinez-Diaz
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background After the approval of nivolumab some time ago it is necessary to analyse if the results of the randomised clinical trials are correlated with usual clinical practice. Purpose In this study we assessed median progression-free survival, over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3067474a44aa6303fa62e4b338e06fdf
https://doi.org/10.1136/ejhpharm-2019-eahpconf.256
https://doi.org/10.1136/ejhpharm-2019-eahpconf.256
Autor:
Mdp Briceño-Casado, JM Borrero-Rubio, E Rios-Sanchez, Silvia Fénix-Caballero, MJ Gandara-LadronDeGuevara, J Diaz-Navarro, Gil-Sierra, FJ Salmeron-Navas, EJ Alegre-Del Rey, C Palomo-Palomo, C Martinez-Diaz
Publikováno v:
Section 2: Selection, Procurement and Distribution.
Background In clinical practice, dimethylfumarate is considered an alternative at the level of conventional systemic drugs in the first line (cyclosporine, methotrexate, acitretin) for moderate-to-severe plaque psoriasis (PP). Purpose To establish wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bfa9d3e5b3e5b65673acc30e87e6c10
https://doi.org/10.1136/ejhpharm-2019-eahpconf.42
https://doi.org/10.1136/ejhpharm-2019-eahpconf.42